OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial Board	152
Editorial Board	92
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	74
Editorial Board	69
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	64
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	62
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	57
Surgery for prolactinoma	56
Thiazide-induced hyponatremia	54
The role of androgens in transgender medicine	45
Sexual health and contraception in the menopause journey	44
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	42
Coronavirus disease 2019 and vitamin D	39
Editorial Board	36
Impulse control disorders and dopamine agonists	35
Cardiometabolic outcomes of early onset hypogonadism in males	34
Editorial Board	34
Remnant lipoprotein particles and cardiovascular disease risk	33
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	31
Haematological actions of androgens	31
Medullary thyroid cancer - An update	27
Editorial Board	27
Radioiodine therapy in the different stages of differentiated thyroid cancer	27
Non-oestrogen-based and complementary therapies for menopause	26
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	25

Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	25
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	25
Metabolic complications and their mechanisms in patients with craniopharyngioma	25
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	24
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	23
Approach to patients with elevated low-density lipoprotein cholesterol levels	23
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	22
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	22
Editorial Board	22
Pathophysiology of thyroid-associated orbitopathy	22
Editorial Board	22
History of androgens and androgen action	21
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Safety of androgen therapy in men with prostate cancer	20
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	20
Localization in primary hyperparathyroidism	19
Editorial Board	19
Hyponatraemic encephalopathy	19
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	18
Editorial Board	18
Diagnosis and treatment of hypernatremia	18
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	17
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	17
Genotype-phenotype correlations in Graves’ disease	17
Diagnostic algorithm of hyponatremia	16
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	16
Type 5 diabetes: A disorder associated with undernutrition: The epidemiology, pathogenesis, clinical features and differential diagnosis	15
Preface	15
Mortality in craniopharyngiomas: Data from the last two decades	15
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	15
Editorial Board	15
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	15
Editorial Board	14
COVID-induced thyroid autoimmunity	14
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	14
Anaplastic thyroid cancer: An update	14
Hormone replacement in disorders of sex development, and long-term effects	14
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	14
Chemokines in thyroid autoimmunity	14
Care quality improvement in differences of sex development	14
Ectopic craniopharyngiomas	13
Preface	13
Best practice & research clinical endocrinology & metabolism prolactinoma	12
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	12
Outcomes of pregnancies complicated by type 2 diabetes	12
Addressing the social determinants of adverse outcomes in pregestational diabetes	12
Genetic endocrine tumours focusing on pituitary tumours	12
The epidemiology of disorders of sex development	12
Strategies for improving the knowledge of patients and carers	12
SARS-CoV-2 infection and its effects on the endocrine system	11

Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	11
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	11
Surgical treatment of thyroid cancer: Established and novel approaches	11
Covid-19 and endocrinology	11
Editorial Board	11
Editorial Board	11
Quality of life in thyroid cancer	10
How best to monitor the specific side effects of medical treatments of Cushing’s disease	10
Hypopituitarism in patients with prolactinomas: a narrative review	10
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	10
New potential treatment options for syndrome of inappropriate antidiuresis	10
Long-term thionamide antithyroid treatment of Graves' disease	9
Adolescent primary hyperparathyroidism	9
Management of patients with statin intolerance	9
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	9
Treatment of chronic hyponatremia and controversy about osmotic demyelination syndrome	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	8
COVID-19 vaccination and thyroiditis	8
Androgen-based therapies in women	8
Current medical treatment and perspective in gonadotroph tumors	8
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	8
Preface	8
Type 2 diabetes and obesity in South Asian patients with polycystic ovary syndrome: the emerging role of metabolomics	8
Burosumab: Current status and future prospects	8
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	8
Editorial Board	8
Real-world value of cabergoline in the treatment of acromegaly	8
Inherited fibroblast growth factor 23 excess	7
Stress and the interaction of the hypothalamic–pituitary–adrenal axis with other pituitary axes and its consequences on muscle mass	7
Hyponatraemia and cancer	7
Androgens part 2: Emerging areas	7
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	6
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	6
Fertility and pregnancy in patients with prolactinoma	6
Vitamin D deficiency or resistance and hypophosphatemia	6
Traumatic brain injury and hypopituitarism	6
Tumor-induced osteomalacia: An overview	6
Novel androgen therapies including selective androgen receptor modulators	6
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	6
Pituitary and SARS CoV-2: An unremitting conundrum	6
Diagnosis and evaluation of sarcopenic obesity	6
Heritable hyperparathyroidism: Genetic insights and clinical implications	6
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	6
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	6
Sexual dysfunction in patients with Type 2 diabetes: A South Asian perspective	6
Thyroid hormones as permissive regulators of skeletal muscle protein accretion and oxidative capacity: Implications for resistance and endurance training	5
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Editorial Board	5
Innovative therapeutics in acromegaly	5
Hypothalamus-sparing surgery in craniopharyngiomas: Oncological and hypothalamic long-term outcomes	5
New advances in menopause symptom management	5
Pituitary dysfunction due to sports injuries	5
Morbidity and mortality in men: Role of androgens	5
Resistant prolactinomas	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Premature ovarian insufficiency, early menopause, and induced menopause	4
Congenital primary hyperparathyroidism	4
Management of non-hepatic distant metastases in neuroendocrine neoplasms	4
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
Androgens, sports, and detection strategies for anabolic drug use	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
The pathophysiology of hypophosphatemia	4
Pathophysiology and aetiologies of hypernatremia	4
Editorial Board	4
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	4
Primary hyperparathyroidism	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas	4
Impact of long-acting growth hormone replacement therapy in adult growth hormone deficiency: Comparison between adolescent, adult, and elderly patients	4
Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients	4
Diagnosis of gestational diabetes: Evidence and pitfalls	4
Broader impact and outcome of human NR5A1/SF1 variants	4